Die meistzitierten Artikel
|
Rang |
Autoren |
Paper |
Zitierungen |
1 | Hodi, FS;...; Schadendorf, D; Hassel, JC;...; Vaubel, JM; Peschel, C;...; Urba, WJ | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma N ENGL J MED 363(8): 711-23 (19 AUG 2010) | 7.443 |
2 | Chapman, PB; Hauschild, A;...; Dummer, R; Garbe, C;...; Schadendorf, D;...; McArthur, GA | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation N ENGL J MED 364(26): 2507-16 (30 JUN 2011) | 4.635 |
3 | Larkin, J;...; Schadendorf, D; Dummer, R;...; Wolchok, JD | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma N ENGL J MED 373(1): 23-34 (2 JUL 2015) | 3.043 |
4 | Robert, C;...; Garbe, C;...; Hauschild, A;...; Wolchok, JD | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma N ENGL J MED 364(26): 2517-26 (30 JUN 2011) | 2.580 |
5 | Robert, C;...; Hassel, JC;...; Mauch, C;...; Schadendorf, D;...; Ascierto, PA | Nivolumab in Previously Untreated Melanoma without BRAF Mutation N ENGL J MED 372(4): 320-30 (22 JAN 2015) | 2.354 |
6 | Flaherty, KT;...; Garbe, C;...; Hassel, JC;...; Mohr, P; Dummer, R; Trefzer, U;...; Utikal, J;...; Becker, JC;...; Schadendorf, D | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma N ENGL J MED 367(2): 107-14 (12 JUL 2012) | 2.089 |
7 | Hauschild, A;...; Gutzmer, R;...; Kaempgen, E;...; Mauch, C;...; Chapman, PB | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial LANCET 380(9839): 358-65 (28 JUL 2012) | 1.714 |
8 | Hodis, E;...; Wagner, SN;...; Schadendorf, D;...; Chin, L | A Landscape of Driver Mutations in Melanoma CELL 150(2): 251-63 (20 JUL 2012) | 1.260 |
9 | Weber, JS;...; Gutzmer, R;...; Hoeller, C;...; Hassel, JC;...; Mohr, P;...; Krackhardt, AM;...; Larkin, J | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial LANCET ONCOL 16(4): 375-84 (APR 2015) | 1.184 |
10 | Robert, C;...; Stroiakovski, D;...; Dummer, R;...; Hauschild, A;...; Schadendorf, D | Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib N ENGL J MED 372(1): 30-9 (1 JAN 2015) | 1.057 |